Compare Trip.com Group Ltd (TCOM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs Viatris Inc — how do they compare? Trip.com Group Ltd trades at $43.83 (market cap $28.12B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Trip.com Group Ltd is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| TCOM | VTRS | |
|---|---|---|
Market Cap | $28.12B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $17.39 |
52-Week Low | $39.84 | $8.74 |
Enterprise Value | $20.82B | $32.00B |
Dividend Yield | 0.42% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Trip.com Group (TCOM) trades at $43.65, up 2.83% with strong fundamentals including a 6.64 P/E ratio and 48.65% net margin. Recent Q1 2026 earnings missed expectations at $0.83 per share versus $0.85 expected, though revenue grew 17% year-over-year. Technical indicators show a bullish overall signal with resistance near $45, while news highlights institutional buying and regulatory scrutiny concerns.
The outlook remains positive with a $56.72 analyst price target implying 30% upside, supported by robust cash flow and expanding profitability. Key risks include Q2 revenue guidance of 3%-8% growth lagging expectations and ongoing antitrust investigations in China that could pressure margins near-term.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
